DenovAI Biotech

At DenovAI Biotech we are re-imagining the future of therapeutic protein design - we believe that humanity is in the midst of a protein design revolution that stands to transform human health and the world around us. Our vision is to revolutionize biologics discovery with our proprietary Gen AI and molecular biophysics platform for the de-novo design of therapeutic proteins, totally from scratch. Focusing on next generation therapeutic antibodies and miniproteins, our vision is to accelerate the pace of biologics discovery from years to weeks, dramatically lower the cost of preclinical development and reduce the high failure rate of drug development - by designing the right molecule, right from the start! DenovAI has been created as a portfolio company of the AION Labs venture studio (https://aionlabs.com), through the investment of leading pharmaceutical companies Pfizer, AstraZeneca, Merck, and Teva, with close support from Amazon Web Services (AWS) and additional financial backing from the Israel Innovation Authority, the Israel Biotech Fund and Amiti Ventures.